Molecular Pituitary Imaging Using 18F-FET PET

Launched by UNIVERSITY OF CAMBRIDGE · Aug 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique called 18F-fluoro-ethyl-tyrosine PET (FET-PET) to see if it can effectively locate pituitary tumors, known as pituitary adenomas, just as well as an existing method called 11C-methionine PET (Met-PET). The study is being conducted at one location and aims to gather information that could help improve how these tumors are detected.

To participate in this trial, you must be at least 18 years old and have a pituitary adenoma that has been suspected based on previous tests or scans. You also need to have had a prior 11C-Met-PET/CT scan. Participants will need to lie still for 30 to 60 minutes during the imaging process. The trial is not open yet for recruiting, meaning they are still preparing to start. If you have any allergies to contrast agents or are pregnant, you would not be eligible to participate. Overall, this study hopes to find better ways to identify pituitary tumors, which could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Participant is willing and able to give informed consent for participation in the study
• • Male or female, age 18 or above
• • Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings
• • Previous 11C-Met-PET/CT
• • Exclusion criteria
• • Inability to give informed consent
• • Pregnancy or suspected pregnancy
• • Inability to lie supine for 30-60 minutes
• • Patient body habitus above scanner dimensions
• • Known allergy to intravenous radiographic contrast agents